{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', 'abnormal and not clinically significant', 'the investigator as belonging to one', 'of the following categories:', 'abnormal and clinically significant', 'Any ECG finding that is judged by the', 'abnormal and not clinically', 'investigator as clinically significant (except at', 'significant', 'the screening visit) will be considered an', 'abnormal and clinically', 'adverse event, recorded on the source', 'significant', 'documentation and in the CRF.The 12 lead', 'Any ECG finding that is judged by', 'ECGs will be interpreted by a cardiologist at', 'the investigator as clinically', 'central diagnostic center. Heart rate and ECG', 'significant (except at the screening', 'intervals (PR, QRS, QT, and QTcF) and clinical', 'visit) will be considered an adverse', 'interpretation will be assessed by the central', 'event, recorded on the source', 'eardiologist, recorded, and monitored as', 'documentation and in the CRF, and', 'described in Section 7.1.2.', 'monitored as described in', 'Section 7.1.2', '8.1. Pharmacokinetic Assessment', 'Plasma samples for both a-HTBZ and \u00df-HTBZ', 'Plasma samples for both a-HTBZ', 'Samples for', 'metabolites will be pooled with previous data', 'and \u00df-HTBZ metabolites will be', 'pharmacokinetic', 'and incorporated into a population', 'pooled with previous data and', 'assessment were', 'pharmacokinetic analysis. The population', 'incorporated into a population', 'updated.', 'pharmacokinetic analysis will result in a final', 'pharmacokinetic analysis. The', 'structural model that best describes the data. A', 'population pharmacokinetic analysis', 'covariate assessment will evaluate the', 'will result in a final structural model', 'relationship between potential covariates (ie,', 'that best describes the data. A', 'body weight, age, height, etc) and', 'covariate assessment will evaluate', 'concentrations of a-HTBZ and \u00df-HTBZ', 'the relationship between potential', 'metabolites. The final population', 'covariates (ie, body weight, age,', 'pharmacokinetic analysis will be included in a', 'height, etc) and concentrations of', 'separate report.', 'a-HTBZ and \u00df-HTBZ metabolites.', 'Blood samples (5 mL) will be collected via', 'The final population', 'venipuncture for plasma oncentration', 'pharmacokinetic analysis will be', 'measurements of TEV 50717 and metabolites', 'included in a separate report.', 'or other analytes.', 'The dates and times of IMP administration and', 'the date and time of each pharmacekinetic', 'sample will be recorded on the source', 'documentation and transcribed onto the CRF.', '9.1 Sample Size and Power Considerations', '127']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Original text with changes shown', 'New wording', 'Reason/Justifi', 'cation for', 'change', '9.5.4.2 Sensitivity Analysis', 'The primary analysis at week 12 will be', 'The primary analysis at week 12', 'Sensitivity', 'repeated on a complete data set using', 'will be repeated on a complete', 'analyses were', 'multiple imputation methodology for', 'data set using multiple', 'simplified and', 'imputing missing data using an MNAR', 'imputation methodology for', 'made', 'missing data assumption to investigate', 'imputing missing data using an', 'consistent with', 'when statistical significance disappears.', 'MNAR missing data assumption', 'Study', 'Using the same repeated measures model as', 'to investigate when statistical', 'TV50717-', 'described for the primary analysis, the', 'significance disappears.', 'CNS-30060.', 'groups will be compared at each of weeks', '2, 4, 6, and 9.', 'An analysis of covariance (ANCOVA)', 'model will be fit using the change from', 'baseline to week 12 as the dependent', 'variable, treatment group, and the baseline', 'value as a covariate. For patients with', 'missing data at week 12, the least favorable', 'change from baseline to week 12 observed', 'in either treatment group will be used as the', 'dependent variable.', 'An ANCOVA model, as described above,', 'will be fit. For patients with missing data at', 'week 12, the last available change from', 'baseline for the patients will be used as the', 'dependent variable.', '9.5.4.3. Key Secondary Efficacy Analyses', 'A hierarchical (fixed-sequence) testing', 'A hierarchical (fixed-sequence)', 'The purpose of', 'approach will be used for the analysis of the', 'testing approach will be used for the', 'the hierarchical', 'primary and key secondary endpoints to', 'analysis of the primary and key', 'analysis was', 'maintain the experiment-wise type I error rate', 'secondary endpoints to maintain the', 'added.', 'of 5%. If an endpoint is not statistically', 'experiment-wise type I error rate of', 'significant, confirmatory hypothesis testing will', '5%. If an endpoint is not statistically', 'not be carried out on the remaining hypotheses,', 'significant, confirmatory hypothesis', '128']\n\n###\n\n", "completion": "END"}